A new class of histamine H3 receptor antagonists derived from ligand based design

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 13, 2007, Pages 3670-3675

  Roche, Olivier ^a   Rodríguez Sarmiento, Rosa María ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

De novo design; Histamine H3 receptor; Pharmacophore model; SAR; Skelgen

Indexed keywords

HISTAMINE H3 RECEPTOR ANTAGONIST;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; NONHUMAN; PHARMACOPHORE; RAT; VALIDATION STUDY;

ANIMALS; BINDING, COMPETITIVE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HISTAMINE ANTAGONISTS; HUMANS; KINETICS; LIGANDS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; RECEPTORS, HISTAMINE H3;

EID: 34250179519     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.056     Document Type: Article

References (34)

1. Sneader W. Drug News Perspect. 14 (2001) 618
2. Hough L.B. Mol. Pharmacol. 59 (2001) 415
3. Thurmond R.L., Desai P.J., Dunford P.J., Fung-Leung W.-P., Hofstra C.L., Jiang W., Nguyen S., Riley J.P., Sun S., Williams K.N., Edwards J.P., and Karlsson L. J. Pharmacol. Exp. Ther. 309 (2004) 404
4. Arrang J.M., Garbarg M., and Schwartz J.C. Neuroscience 23 (1987) 149
5. Schlicker E., and Kathmann M. In: Leurs R., and Timmerman H. (Eds). The Histamine H3 Receptor; a Target for New Drugs. 1st ed. (1998), Elservier Science B.V., Amsterdam 13-26
6. Stark H. Expert Opin. Ther. Pat. 13 (2003) 851
7. Leurs R., Blandina P., Tedford C., and Timmerman H. Trends Pharmacol. Sci. 19 (1998) 177
8. Rouleau A., Ligneau X., Tardivel-Lacombe J., Morisset S., Gbahou F., Schwartz J.C., and Arrang J.M.Brit. J. Pharmacol. 135 (2002) 383
9. Takahashi K., Tokita S., and Kotani . J. Pharmacol. Exp. Ther. 307 (2003) 213
10. Witkin J.M., and Nelson D.L. Pharmacol. Therapeut. 103 (2004) 1
11. Alguacil L.F., and Perez-Garcia C. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 303
12. Hancock A.A., and Brune M.E. Expert Opin. Invest. Drugs 14 (2005) 223
13. Hancock A.A. Curr. Opin. Invest. Drugs 4 (2003) 1190
14. Yang R., Hey J.A., Aslanian R., and Rizzo C.A. Pharmacology 66 (2002) 128
15. Rivara S., Mor M., Bordi F., Silva C., Zuliani V., Vacondio F., Morini G., Plazzi P.V., Carrupt P.-A., and Testa B. Drug Des. Discov. 18 (2003) 65
16. Yao B.B., Hutchins C.W., Carr T.L., Cassar S., Masters J.N., Bennani Y.L., Esbenshade T.A., and Hancock A.A. Neuropharmacology 44 (2003) 773
17. Stark H., Sippl W., Ligneau X., Arrang J.M., Ganellin C.R., Schwartz J.C., and Schunack W. Bioorg. Med. Chem. Lett. 11 (2001) 951
18. De Esch I.J., Mills J.E., Perkins T.D., Romeo G., Hoffmann M., Wieland K., Leurs R., Menge W.M., Nederkoorn P.H., Dean P.M., and Timmerman H. J. Med. Chem. 44 (2001) 1666
19. De Esch I.J.P., Timmerman H., Menge W.M.P.B., and Nederkoorn P.H.J. Arch. Pharm. (Weinheim, Germany) 333 (2000) 254
20. Apodaca R., Dvorak C.A., Xiao W., Barbier A.J., Boggs J.D., Wilson S.J., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3938
21. Faghih R., Dwight W., Bao Pan J., Fox G.B., Krueger K.M., Esbenshade T.A., McVey J.M., Marsh K., Bennani Y.L., and Hancock A.A. Bioorg. Med. Chem. Lett. 13 (2003) 1325
22. Cowart M., Pratt J.K., Stewart A.O., Bennani Y.L., Esbenshade T.A., and Hancock A.A. Bioorg. Med. Chem. Lett. 14 (2004) 689
23. Keith J.M., Gomez L.A., Letavic M.A., Ly K.S., Jablonowski J.A., Seierstad M., Barbier A.J., Wilson S.J., Boggs J.D., Fraser I.C., Mazur C., Lovenberg T.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 17 (2007) 702
24. Letavic M.A., Keith J.M., Jablonowski J.A., Stocking E.M., Gomez L.A., Ly K.S., Miller J.M., Barbier A.J., Bonaventure P., Boggs J.D., Wilson S.J., Miller K.L., Lord B., McAllister H.M., Tognarelli D.J., Wu J., Abad M.C., Schubert C., Lovenberg T.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 17 (2007) 1047
25. Letavic M.A., Keith J.M., Ly K., Barbier A.J., Boggs J.D., Wilson S.J., Lord B., Lovenberg T.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 17 (2007) 2566
26. Dean P.M., Firth-Clark S., Harris W., Kirton S.B., and Todorov N.P. Expert Opin. Drug Disc. 1 (2006) 179
27. Lloyd D.G., Buenemann C.L., Todorov N.P., Manallack D.T., and Dean P.M. J. Med. Chem. 47 (2004) 493
28. Stahl M., Todorov Nikolay P., James T., Mauser H., Boehm H.-J., and Dean Philip M. J. Comput. Aided Mol. Des. 16 (2002) 459
29. Tori M., Hamaguchi T., Sagawa K., Sono M., and Asakawa Y. J. Org. Chem. 61 (1996) 5362
30. Saturation binding experiments were performed using HR3-CHO membranes prepared as described in:. Takahashi K., Tokita S., and Kotani H. J. Pharmacol. Exp. Ther. 307 (2003) 213
31. 50 based on Cheng-Prusoff equation:. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
32. For a more detailed description see: Gatti, S.; Hertel, C.; Nettekoven, M.; Plancher, J.-M.; Raab, S.; Roche, O.; Rodriguez-Sarmiento, R.-M. PCT Int. Appl. 2005, WO2005117865.
33. Membranes and protocols originated from Euroscreen. For more information, see: characterization of histaminergic receptors Current Protocols in Pharmacology, Ed. J. Wiley & Sons, 2006; Vol. 1, Chapter 19, pp 1-19.
34. 50 > 10 μM ).